One
concern expressed about PEP is cost. Anti-HIV drugs are a lot more expensive than
condoms. However, at around £600 for a month's triple combination therapy, the
cost of one course of PEP for a single individual compares extremely favourably
with the lifetime costs of treating the same individual for HIV.
A 2009
review1 of
the cost-effectiveness of PEP for the United Kingdom commented that “It
is not possible to draw conclusions on the clinical effectiveness of
non-occupational PEP for HIV because of the limited evidence in terms of the quantity
and quality of studies.”
However it found
that four
economic evaluations using evidence on effectiveness taken from the use of PEP
in the occupational setting indicate that PEP might be cost-effective with certain
populations, though it cautioned on the generalisability of studies conducted
in other countries.
The
cost–effectiveness of an intervention such as PEP can only be meaningfully
calculated in terms of the amount of money that would need to be spent to prevent
a single infection. On average, no more than about one out of every 300 people
who have a single episode of unprotected receptive anal sex with an
HIV–positive person becomes infected as a result.2
So if all 300 came forward for PEP after their risk exposure, 299 would be
treated 'unnecessarily', because they would not have become infected regardless
of whether or not they received PEP. If doctors have to treat 300 people in
order to prevent the one single infection, the cost of preventing that infection
would be 300 times £750, which makes £225,000. This begins to approximate the
likely lifetime drug costs of treating someone with HIV, which for a 30-year
post-treatment lifespan in the UK
would be around £300,000. However the cost of PEP per infection prevented is
still likely to be much lower when all the costs of lifetime treatment in
addition to drugs (staff, monitoring etc.) are included.
The
cost–effectiveness of PEP could be improved by using fewer or cheaper drugs;
for example, if only two nucleoside reverse transcriptase inhibitors (NRTIs) were
used, or if an additional protease inhibitor was reserved only for specific
cases of the greatest risk, the cost per course of PEP would be approximately
halved.
Moreover,
PEP is more cost–effective if it is delivered only to people whose
circumstances mean that they are most at risk of becoming infected (effectively
reducing the proportion of recipients who are being treated 'unnecessarily').
Possible criteria for prioritisation include limiting PEP to cases in which
people have had a risk encounter with someone who is definitely HIV positive.
This is the case in UK national
guidelines for any sexual exposure other than receptive anal intercourse, even though
the US
guidelines for occupational use do not carry such a restriction.
A study
published in January 20043
attempted to calculate the cost-effectiveness of PEP by looking at 401 people
who had sought PEP in San Francisco.
The
group included men and women who sought PEP for incidents of unprotected anal
and/or vaginal intercourse and needle-sharing. The researchers concluded that,
given their risk behaviour, PEP reduced the HIV infections that would have been
expected in the group by 53%. They estimated that 2.36 HIV infections would
have been expected in the 401 people during the study period, and PEP reduced
this to 1.1 infections.
This 53%
reduction saved 11.74 quality-adjusted life years (QALYs). This measurement,
frequently used in cost-benefit calculations, means that, for those who used it
successfully, PEP should lead to an extra 11.74 years of reasonable health.
This in turn, it was calculated, would save a total of US$281,323 in future
HIV-related medical costs. When all factors were taken into account, the cost
of PEP per QALY saved was US$14,449. This is easily under the US threshold for the definition of medical
cost-effectiveness, which is $40,000 to $60,000 per QALY (about £30,000 in the UK). By
comparison, a similar cost-effectiveness study4 showed
that HIV combination therapy resulted in a cost of US$23,000 per QALY saved.
This
study found that PEP, given to the general at-risk population, did work out to
be much less cost-effective than other HIV prevention methods. As an example, one
risk-reduction programme for at-risk women attending an urban primary healthcare
clinic, which produced a significant increase in condom use, cost about US$2000
per QALY.5 A
similar programme for gay men,6
was cost-saving: the cost of likely future treatment and care of those infected
without the programme outweighed the cost of delivering the programme to the
whole group.
PEP for
gay men in the San Francisco
study was more cost-effective than for the group as a whole: US$8607 per QALY
saved. However, when it came to gay men who had been receptive partners in
unprotected anal sex, it found that PEP was actually cost-saving. The cost per
infection averted for this group was US$177,293 – which is less than the likely
cost of their lifetime HIV treatment if they had not received successful PEP.
On the other hand, PEP for gay men on the insertive end of unprotected anal sex
(i.e. ‘tops’) was not considered cost-effective.
The
variation seen in cost-effectiveness between subgroups of different populations
is not surprising, given that you need to provide PEP
to the people most at-risk for it to be cost-effective. The Health Protection
Agency7 estimates
that gay men who are the passive partner in unprotected anal intercourse have a
1-in-33 risk of being infected with HIV if they are certain their partner is
HIV-positive, but a 1-in-222 risk if they do not know the HIV status of their
partner. They estimate that gay men who are the active partner in unprotected
anal intercourse have a 1-in-555 risk of being infected with HIV if they are
certain their partner is HIV-positive, but a 1-in-11,111 risk if they do not
know the HIV status of their partner. However, other factors such as
geographical location, sexually transmitted infections (STIs), viral load and
bleeding may affect the risk estimate, so there is likely to be a range of risk
of transmission rather than an exact value.
In
short, if PEP in the UK is offered
to gay men who have been the passive partner in unprotected anal intercourse
and/or who have known HIV-positive partners, PEP
could potentially save as much money as providing condoms and safer-sex
education, as long as PEP is not
routinely relied upon as a substitute for these other safer-sex practices.